Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alectinib and Bevacizumab in ALK-positive non-squamous NSCLC
NCT03779191Phase 2Completed
- Start
- Apr 2020
- Primary completion
- Aug 2022
- Modality
- Fragment-Derived Small Molecules, Monoclonal Antibodies, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alectinib and bevacizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC). Primary endpoint: Progression-Free Survival at 18 months. Started Apr 2020; status: completed.
02
Drugs
alectinibbevacizumab
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT03779191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03779191.